Zealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/9/2026
- S&P 500, Nasdaq end lower as crude prices jump, chip stocks weigh
- Oil rises 4% on revived Middle East worries, Hurricane Isaias supply disruption
- Chipotle, Starbucks shares volatile after report of potential takeover
- Why Citi says the Fed could be setting up for a dovish surprise
- Alphabet shares rise as Google pushes Gemini deeper into enterprise AI
| (NASDAQ: ZEAL) | Delayed: 17.59 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $17.59 | 52 Week High | $ | |||
| Open | $1.35 | 52 Week Low | $ | |||
| Day High | $17.59 | P/E | N/A | |||
| Day Low | $17.59 | EPS | $ | |||
| Volume | 15,962 | |||||
